{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:53:54Z","timestamp":1761062034656,"version":"3.40.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The National Key Research and Development Program of China","award":["2021YFC2009300,2021YFC2009303"],"award-info":[{"award-number":["2021YFC2009300,2021YFC2009303"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:p>To evaluate the long-term clinical outcomes of iodine-125 low dose-rate brachytherapy (LDR-BT)-based treatment approaches for\u2005\u2264\u2005cT3 prostate cancer (PC) patients in China, as well as the effects on the PC immune microenvironment. Data was retrospectively collected from 237 patients with\u2005\u2264\u2005cT3 PC who were treated with radical prostatectomy (RP) or LDR-BT alone or in combination with androgen deprivation therapy (ADT), and biochemical progression-free survival (bPFS), prostate cancer-specific survival (PCSS) and overall survival (OS) rates were compared. In 63 cases, PC patients received RP after biopsy, received at least 6 months of ADT before RP, or received LDR-BT and deferred limited transurethral resection of the prostate (TURP). Immunohistological analyses and expression comparisons of programmed death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs, expressing CD3, CD4, CD8, and PD-1) on tissue sections from archival prostate biopsy samples with corresponding TURP or RP history were performed by paired <jats:italic toggle=\"yes\">t<\/jats:italic> test. The 8-year bPFS, PCSS, and OS rates for LDR-BT and RP were 53.4% and 63.6%, 84.9% and 86.8%, and 63.8% and 70.2%, respectively, although these differences were not statistically significant. PD-L1 was expressed in 35 of 63 cases. The average infiltration scores of TILs (expressing CD3, CD4, and CD8) were 3.6 (1\u20135), 2.90 (1\u20135), and 2.46 (1\u20135), respectively. PD-1\u2005+\u2005T cells were seen in 55.6% of cases, with an average score of 0.89 (range: 0\u20133). In TURP tissue samples from 23 patients, CD3+, CD4+, and CD8\u2005+\u2005T cells increased significantly. PD-1\u2005+\u2005T cells exhibited a moderate increase, with conversion to positive PD-1 expression in T cells observed in 13 out of 14 cases. The PD-L1 expression score of PC cells was significantly elevated, with conversion to positive in 8 of 9 cases. LDR-BT monotherapy and combination therapy with external beam radiotherapy (EBRT) and ADT are suitable treatment approaches for low-risk and intermediate- or high-risk PC, respectively. Most TILs in PC are not tumor antigen-specific T-cells. LDR-BT can stimulate anti-tumor immunity during a narrow time window and should be combined with immunotherapy as an auxiliary therapy.<\/jats:p>","DOI":"10.1097\/md.0000000000040574","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T20:00:52Z","timestamp":1732564852000},"page":"e40574","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Long-term outcome and antitumor immune activation response in prostate cancer treated with low-dose-rate brachytherapy"],"prefix":"10.1097","volume":"103","author":[{"given":"Zengzeng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, Tianjin Beichen Traditional Chinese Medicine Hospital, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Tianjin Beichen Hospital, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2021.12.047","article-title":"GEC-ESTRO ACROP prostate brachytherapy guidelines.","volume":"167","author":"Henry","year":"2022","journal-title":"Radiother Oncol"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in Asian men.","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat Rev Urol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"954992","DOI":"10.3389\/fimmu.2022.954992","article-title":"Managing the TME to improve the efficacy of cancer therapy.","volume":"13","author":"Bilotta","year":"2022","journal-title":"Front Immunol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy.","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41416-020-0956-x","article-title":"Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.","volume":"123","author":"Philippou","year":"2020","journal-title":"Br J Cancer"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"e000792","DOI":"10.1136\/jitc-2020-000792","article-title":"High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.","volume":"8","author":"Keam","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R7-20250503","first-page":"72","article-title":"125I low-dose-rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer.","volume":"18","author":"Zhou","year":"2019","journal-title":"Oncol Lett"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/pros.22476","article-title":"T cells localized to the androgen-deprived prostate are TH1 and TH17 biased.","volume":"72","author":"Morse","year":"2012","journal-title":"Prostate"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer:recommendations of the RTOG-ASTRO Phoenix Consensus Conference.","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1158\/1078-0432.CCR-15-2042","article-title":"The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer.","volume":"22","author":"Gevensleben","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41379-019-0349-y","article-title":"Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.","volume":"33","author":"Widmaier","year":"2020","journal-title":"Mod Pathol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1080\/15384047.2016.1235666","article-title":"Tumor infiltrating T lymphocytes expressing FoxP3,CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.","volume":"17","author":"Nardone","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.brachy.2014.08.047","article-title":"Long-term oncologic outcomes of radical prostatectomy compared with brachytherapy-based approaches for intermediate- and high-risk prostate cancer.","volume":"14","author":"Crook","year":"2015","journal-title":"Brachytherapy"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"20150981","DOI":"10.1259\/bjr.20150981","article-title":"Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy:practice and outcome analysis in a series of 2237 patients from 11 institutions.","volume":"89","author":"Fellin","year":"2016","journal-title":"Br J Radiol"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen Suppression Combined with Elective Nodal and Dose EscalatedRadiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high-and intermediate-risk prostate cancer.","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.3390\/cancers13194757","article-title":"Overcoming immune resistance in prostate cancer: challenges and advances.","volume":"13","author":"Movassaghi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"52810","DOI":"10.18632\/oncotarget.10547","article-title":"Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.","volume":"7","author":"Graff","year":"2016","journal-title":"Oncotarget"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-017-0232-7","article-title":"Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer:case report of two patients.","volume":"5","author":"Cabel","year":"2017","journal-title":"J ImmunoTher Cancer"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"26789","DOI":"10.18632\/oncotarget.15817","article-title":"The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.","volume":"8","author":"Ness","year":"2017","journal-title":"Oncotarget"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1.","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2326-6066.CIR-19-0398","article-title":"TCR repertoire diversity of peripheral PD-1+CD8+ T cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer.","volume":"8","author":"Han","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s40425-019-0704-z","article-title":"Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.","volume":"7","author":"Dudzinski","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.31557\/APJCP.2019.20.11.3421","article-title":"Increased CD8 tumor infiltrating lymphocytes in colorectal cancer microenvironment supports an adaptive immune resistance mechanism of PD-L1 expression.","volume":"20","author":"Sudoyo","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1016\/j.celrep.2019.11.113","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression.","volume":"29","author":"Garcia-Diaz","year":"2019","journal-title":"Cell Rep"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.21037\/atm-22-6049","article-title":"Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review.","volume":"10","author":"Wang","year":"2022","journal-title":"Ann Transl Med"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.it.2024.02.005","article-title":"Regulation and impact of tumor-specific CD4+ T cells in cancer and immunotherapy.","volume":"45","author":"Guo","year":"2024","journal-title":"Trends Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:34:19Z","timestamp":1746318859000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":28,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040574","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}